<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment outcome of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> has been improved since molecular targeted drugs including rituximab became clinically available </plain></SENT>
<SENT sid="1" pm="."><plain>However, treatment for relapsed or refractory <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has not been fully established </plain></SENT>
<SENT sid="2" pm="."><plain>As second-line therapy for patients with relapsed/refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, chemotherapy including <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> or <z:chebi fb="0" ids="35584">purine</z:chebi> analogues, high-dose chemotherapy followed by autologous stem cell transplantation (SCT), and allogeneic SCT are usually selected </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, we can also select new therapies including new anti-CD20 monoclonal antibody (MoAb)(IMMU-106(hA20)), anti-CD22 MoAb (epratuzumab), and radioimmunotherapy including Y-90 ibritumomab and I-131 tositumomab </plain></SENT>
</text></document>